Klaus-Uwe Kirchgaessler
Overview
Explore the profile of Klaus-Uwe Kirchgaessler including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
38
Citations
1162
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wells A, Jacob J, Sverzellati N, Cross G, Barnett J, De Lauretis A, et al.
Respir Res
. 2024 Jan;
25(1):33.
PMID: 38238788
Background: No single pulmonary function test captures the functional effect of emphysema in idiopathic pulmonary fibrosis (IPF). Without experienced radiologists, other methods are needed to determine emphysema extent. Here, we...
2.
Maher T, Schiffman C, Kreuter M, Moor C, Nathan S, Axmann J, et al.
Respir Res
. 2022 Nov;
23(1):307.
PMID: 36369156
Background: Patients with interstitial lung disease (ILD) require regular physician visits and referral to specialist ILD clinics. Difficulties or delays in accessing care can limit opportunities to monitor disease trajectory...
3.
Harari S, Wells A, Wuyts W, Nathan S, Kirchgaessler K, Bengus M, et al.
Eur Respir Rev
. 2022 Aug;
31(165).
PMID: 36002171
There is a need for clinical trial end-points to better assess how patients feel and function, so that interventions can be developed which alleviate symptoms and improve quality of life....
4.
Molina-Molina M, Kreuter M, Cottin V, Corte T, Gilberg F, Kirchgaessler K, et al.
Front Med (Lausanne)
. 2022 Jul;
9:897102.
PMID: 35783648
Clinical Trial Registration: ClinicalTrials.gov, identifier: NCT03099187.
5.
Wuyts W, Dahlqvist C, Slabbynck H, Schlesser M, Gusbin N, Compere C, et al.
Pulm Ther
. 2022 Apr;
8(2):181-194.
PMID: 35429319
Introduction: The PROOF registry is a prospective, observational study that aimed to monitor disease progression in a real-world cohort of patients with idiopathic pulmonary fibrosis (IPF). Here, longitudinal quality-of-life (QoL)...
6.
Kreuter M, Maher T, Corte T, Molina-Molina M, Axmann J, Gilberg F, et al.
Adv Ther
. 2021 Dec;
39(2):1081-1095.
PMID: 34936057
Introduction: There are currently no approved treatments solely for unclassifiable interstitial lung disease (uILD); however, a recent trial showed this population can benefit from pirfenidone. We report a subgroup analysis...
7.
Jouneau S, Crestani B, Thibault R, Lederlin M, Vernhet L, Yang M, et al.
Respiration
. 2021 Oct;
101(2):142-154.
PMID: 34610600
Background: Weight loss is frequently reported in patients with idiopathic pulmonary fibrosis (IPF) and may be associated with worse outcomes in these patients. Objective: The aim of this study was...
8.
Wijsenbeek M, Bendstrup E, Valenzuela C, Henry M, Moor C, Jouneau S, et al.
Adv Ther
. 2021 Jun;
38(7):4040-4056.
PMID: 34117601
Introduction: Disease behaviour may guide diagnosis and treatment decisions in patients with interstitial lung disease (ILD). STARLINER aimed to characterise disease behaviour in patients with suspected ILD during the peri-diagnostic...
9.
Kreuter M, Lee J, Tzouvelekis A, Oldham J, Molyneaux P, Weycker D, et al.
Am J Respir Crit Care Med
. 2021 Jan;
204(1):74-81.
PMID: 33434107
There is an urgent need for simple, cost-effective prognostic biomarkers for idiopathic pulmonary fibrosis (IPF); biomarkers that show potential include monocyte count. We used pooled data from pirfenidone and IFNγ-1b...
10.
Behr J, Nathan S, Wuyts W, Mogulkoc Bishop N, Bouros D, Antoniou K, et al.
Lancet Respir Med
. 2020 Aug;
9(1):85-95.
PMID: 32822614
Background: The benefit of sildenafil in patients with advanced idiopathic pulmonary fibrosis (IPF) at risk of poor outcomes from pulmonary hypertension, whether already present or likely to develop, is uncertain....